Progress in Neuro-Psychopharmacology and Biological Psychiatry
October 1, 2022
Francisco de Borja Belloch, M. Cortés-Erice, E. Herzog et al.
The NMDA antagonist ketamine demonstrated a fast antidepressant activity in treatment-resistant depression. Pre-clinical studies suggest that de novo synthesis of the brain-derived neurotrophic factor (BDNF) in the PFC might be involved in the rapid antidepressant action of ketamine. Applying a genetic model of impaired glutamate release, this study aims to further identify the molecular...
Genetic Engineering & Biotechnology News
October 1, 2022
K. Liszewski
A new model of psilocybin therapy is being developed by Compass Pathways, a mental health company. This model involves the administration of a synthetic psilocybin in conjunction with psychological support in order to treat conditions such as treatment-resistant depression. Most recently, Compass announced the launch of a Phase II trial to investigate the efficacy of its synthetic psilocybin...
Neuropharmacology
October 1, 2022
Atsushi Suzuki, Hiroe Hara, H. Kimura
Ketamine exerts rapid and long-lasting antidepressant effects in patients with treatment-resistant depression. However, its clinical use is limited by its undesirable psychotomimetic side effects. Accumulating evidence from preclinical studies has shown that the antidepressant effects of ketamine are dependent on α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R) activation,...
International Journal of Drug Policy
October 2022
Adam W. Levin, Paul Nagib, Selina Deiparine et al.
Evidence points to an incongruence between international drug policy and expert opinion about safety, abuse potential, and therapeutic potential of specific drugs. However, no prior studies have directly explored psychiatrists' attitudes about the current drug schedule. Therefore, we examined whether American psychiatrists' perceptions of four psychoactive drugs differed from those indicated by...
Current diabetes reports
October 1, 2022
Hailey Inverso, Hailey R Moore, Francesca Lupini et al.
Mindfulness-based interventions (MBIs) focus on promoting nonjudgmental, purposeful awareness of the present experience, and they include specific components such as body scan, meditation, and breathing techniques for healthier coping with stress and reduced negative affect. In adult populations with chronic illness (e.g., type 1 diabetes [T1D], type 2 diabetes [T2D], overweight), MBIs have...
Mindfulness
October 1, 2022
Itamar Shapira, Joshua Richman, Thaddeus W W Pace et al.
This study evaluates the effects of treatment with mindfulness-based stress reduction (MBSR) compared to the active control, present-centered group therapy (PCGT), on morning plasma cortisol, interleukin-6 (IL-6), and C-reactive protein (CRP) in veterans diagnosed with post-traumatic stress disorder (PTSD). In a post hoc exploratory analysis, we pooled biomarkers and clinical outcomes of...
Sleep Medicine
October 1, 2022
Maurice Ohayon, Amir Pakpour
Sleep paralysis is a common phenomenon which causes and consequences are seldomly studied. The aim of this study was to investigate the incidence and prevalence of sleep paralysis (SP) in the American adult population and its evolution on a 3-year period. This longitudinal study was conducted between 2002 and 2015 and included a representative sample of the US general population. A total of...
Neuroscience
October 1, 2022
Mengke Zhang, Dongbin Lyu, Fan Wang et al.
Major depressive disorder is a burdensome condition with few treatment options, and traditional antidepressants are characterized by slow onset. Sub-anesthetic ketamine has rapid-onset effects for the treatment of major depressive disorder (MDD), the mechanisms of which remain elusive. In this study, we explored whether neuroplasticity, autophagy, and ferroptosis in the habenular nucleus are...
Current Psychiatry Reports
October 1, 2022
Gregory S. Barber, Scott T Aaronson
56 citations
Few treatments are available for patients with mood disorders or post-traumatic stress disorder (PTSD) who have already failed multiple interventions. After several decades when research into psychedelics was effectively halted by federal legislation, the past several years have shown the re-emergence of thoughtful investigations studying the utility of compounds such as...
Pharmacological Reviews
October 1, 2022
Anna U. Odland, Jesper L. Kristensen, Jesper T. Andreasen
23 citations
Psychedelic-assisted psychotherapy holds great promise in the treatment of mental health disorders. Research into 5-hydroxytryptamine 2A receptor (5-HT2AR) agonist psychedelic compounds has increased dramatically over the past two decades. In humans, these compounds produce drastic effects on consciousness, and their therapeutic potential relates to changes in the processing of emotional,...